Entresto Dosing Recommendations
Start Entresto at 49/51 mg twice daily in most patients, titrating to the target dose of 97/103 mg twice daily after 2-4 weeks, with dose adjustments required for severe renal impairment (eGFR <30), moderate hepatic impairment, or patients not previously on ACE inhibitors/ARBs. 1
Standard Dosing Algorithm
Initial Dose Selection
For most patients:
- Start at 49/51 mg twice daily 1
- Titrate to target dose of 97/103 mg twice daily after 2-4 weeks 1
- This applies to patients already on adequate doses of ACE inhibitors or ARBs
For patients NOT on ACE inhibitors/ARBs or on low doses:
- Start at 24/26 mg twice daily (half the standard starting dose) 1
- Increase every 2-4 weeks following standard escalation 1
- The 2021 ACC Expert Consensus supports direct-to-ARNI initiation without requiring ACE inhibitor pre-treatment, based on PIONEER-HF and PROVE-HF data showing safety and efficacy 2
Critical Washout Period
If switching from an ACE inhibitor:
- Mandatory 36-hour washout period before starting Entresto 1
- This is a contraindication due to angioedema risk 2
Dose Adjustments for Special Populations
Severe Renal Impairment (eGFR <30 mL/min/1.73 m²)
- Start at 24/26 mg twice daily 2, 1
- Double the dose every 2-4 weeks to target of 97/103 mg twice daily as tolerated 2
- No adjustment needed for mild-to-moderate renal impairment (eGFR 30-59 mL/min/1.73 m²) 2
The evidence shows sacubitril/valsartan actually preserves renal function in heart failure patients, with studies demonstrating improvements in eGFR even in those with baseline renal dysfunction 3, 4. Pharmacokinetic data reveals that while sacubitrilat exposure increases 2.1-2.7 fold in renal impairment, the drug remains well-tolerated 5.
Moderate Hepatic Impairment (Child-Pugh B)
- Start at 24/26 mg twice daily 2, 1
- Double the dose every 2-4 weeks to target of 97/103 mg twice daily as tolerated 2
- No adjustment needed for mild hepatic impairment (Child-Pugh A) 2
- Contraindicated in severe hepatic impairment (Child-Pugh C) 2
Titration Schedule
Standard titration:
- Assess tolerability at 2-4 weeks 1
- If tolerated, double the dose 1
- Continue until reaching target dose of 97/103 mg twice daily 1
Monitoring during titration:
- Blood pressure (watch for SBP <100 mmHg) 2
- Electrolytes (particularly potassium >5.5 mEq/L) 2
- Renal function (eGFR changes) 2
The TITRATION trial demonstrated that both 3-week and 6-week uptitration regimens are well-tolerated, with 76% of patients achieving and maintaining target dose 6. However, real-world data shows only 19-27% reach target dose in clinical practice, often due to slower titration or blood pressure concerns 7, 8.
Key Contraindications and Cautions
Absolute contraindications:
- Within 36 hours of ACE inhibitor use 2, 1
- History of angioedema with ACE inhibitor or ARB 2, 1
- Pregnancy 2, 1
- Severe hepatic impairment (Child-Pugh C) 2
- Concomitant aliskiren use in diabetic patients 2
Exercise caution with:
Clinical Pearls
Direct-to-ARNI approach: The 2021 ACC guidelines now recommend initiating Entresto directly without ACE inhibitor pre-treatment in appropriate patients, based on evidence showing improved early clinical outcomes and no unexpected adverse effects 2. This represents a shift from earlier practice requiring ACE inhibitor stabilization first.
Dose-response relationship: Higher doses are associated with significantly better outcomes. Real-world data shows patients on higher terminal doses experience 1.5-2.7 times fewer all-cause hospitalizations and 21-48% lower total healthcare costs 8.
Renal protection: Despite initial concerns, Entresto demonstrates renoprotective effects. The drug likely reduces doubling of serum creatinine (RR 0.77) compared to ACE inhibitors/ARBs 4. Even in patients with baseline renal dysfunction, eGFR improvements of 4.1 mL/min/1.73 m² have been observed 3.
Tolerability in low-dose starters: For patients with concerns about hypotension, starting at 25 mg twice daily (though not FDA-approved) has shown feasibility in observational studies, with similar NT-proBNP reductions and LVEF improvements as standard dosing 9. However, the FDA-approved lowest dose remains 24/26 mg twice daily 1.